Company overview
Basic information
Company name
Jutero, MB
Company code
305892392
Registered address
Klaipėda, Alksnynės g. 15A-15, LT-93154
Registration date
2021-09-07
Company age: 5 y.
Contact information
Edit data
Phone
Email
Not disclosed
(personal)
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Retail sale of pharmaceutical products
Ownership form
Private without foreign capital
MB Jutero
Company code: 305892392
Address: Klaipėda, Alksnynės g. 15A-15, LT-93154
Download a detailed company report
Make confident decisions with all the information about Jutero, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.
Description
This description was generated by artificial intelligence.
Jutero, MB (company code 305892392) is an operational private small partnership registered on 7 September 2021. It is classified as a micro company in the national private non-financial companies sector and is privately owned, with Lithuanian natural and legal persons holding more than 50% of authorised capital and no foreign investor capital. Governance is described as CEO only. The company is based in Klaipeda, Klaipeda city municipality, Klaipeda county, at Alksnynes g. 15A-15, LT-93154.
Its registered activity is EVRK code G.47.73.00, Retail sale of pharmaceutical products. Financially, the company recorded revenue of EUR 34.2 thousand in 2025, up from EUR 24.0 thousand in 2024 and EUR 18.9 thousand in 2023. Net profit was EUR 10.1 thousand in 2025, compared with EUR 6.6 thousand in 2024 and EUR 10.6 thousand in 2023. The 2025 profit margin was 29.4%, after 27.4% in 2024 and 55.8% in 2023. Equity increased to EUR 30.0 thousand in 2025, while total assets reached EUR 37.1 thousand and liabilities were EUR 7.1 thousand. Staff information is limited; the only provided average employee figure is 1 in 2023, and the latest staff year in the dataset is 2026 so far.
Its registered activity is EVRK code G.47.73.00, Retail sale of pharmaceutical products. Financially, the company recorded revenue of EUR 34.2 thousand in 2025, up from EUR 24.0 thousand in 2024 and EUR 18.9 thousand in 2023. Net profit was EUR 10.1 thousand in 2025, compared with EUR 6.6 thousand in 2024 and EUR 10.6 thousand in 2023. The 2025 profit margin was 29.4%, after 27.4% in 2024 and 55.8% in 2023. Equity increased to EUR 30.0 thousand in 2025, while total assets reached EUR 37.1 thousand and liabilities were EUR 7.1 thousand. Staff information is limited; the only provided average employee figure is 1 in 2023, and the latest staff year in the dataset is 2026 so far.